Drugs / HG381
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04998422 | Oct 2021 → Dec 2025 overdue | neoplasm | HitGen Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HG381 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04998422 ↗ |
| Route | Intravenous | “HG381 will be administered as IV injection.” NCT04998422 ↗ |